Drug discovery

#Characterisation #Drug discovery #Hits #Kinetics #Library screening

Creoptix launches new way of measuring kinetics to accelerate drug discovery

Creoptix, a Switzerland-based company focused on next-generation bioanalytical instruments, has launched waveRAPID (Repeated Analyte Pulses of Increasing Duration), a novel, label-free kinetic measurement method that is said to be faster than traditional kinetics. The company developed the Creoptix WAVEsystem to enable molecular interactions to be studied in real time, aimimng… Read More

#News

#Clinical trials #Drug discovery

Clinical trial standard looks to provides global benchmark

GCSA is supporting the UK clinical research industry by providing an internationally-recognised quality benchmark for sites focused on attracting commercial clinical trials to bring the most innovative treatments to patients. Following the rapid approval of COVID-19 vaccines from both Pfizer-BioNTech and Oxford University/AstraZeneca, the UK’s ability to provide a world-leading… Read More

#News

#Biopharmaceutical #Drug discovery #Ion channels

Metrion Biosciences and Sosei Heptares form strategic drug discovery collaboration

Metrion Biosciences, the specialist ion channel CRO and drug discovery company and Sosei Group, an international biopharmaceutical group, will apply Sosei Heptares’ structure-based drug design (SBDD) expertise and platform to ion channels for the first time through a new strategic collaboration. Ion channels are a class of integral membrane proteins… Read More

#News

#Cell culture #Drug discovery #Organ-on-a-chip

Sitting down with…CN Bio

CN Bio is a cell culture company whose mission is to transform the way human-relevant pre-clinical data is generated by developing the most complete model of the human ‘body-on-a-chip’ in the laboratory.  Achieving this is what drives the company’s future initiatives, CEO Dr David Hughes told Lu Rahman. CN Bio… Read More

#Editor's Choice #Exclusive Content #News #Opinion

#DNA #Drug discovery #Lead optimisation #Screening

X-Chem acquires IntelliSyn and AviSyn to boost drug discovery service

X-Chem, provider of DNA-Encoded Library (DEL)-based discovery services, has acquired IntelliSyn, a Montreal-based drug discovery services company and its US-based sister company, AviSyn. The transaction will enable the company to offer a complete, seamless solution for screening, hit validation and lead optimisation on existing and new markets. Financial details of… Read More

#News

#AI / data analytics / healthtech / informatics #Business #Drug development #Drug discovery #Narrated podcasts

The Business Side of Drug Discovery

Today’s episode on the topic of The Business Side of Drug Discovery, covers 3 articles taken from the most recent Fall issue of DDW. These articles are titled: Building the foundations for post COVID-19 R&D, Opportunity Knocks: Why compound screening libraries are worth the investment, and How to achieve data driven R&D at speed… Read More

#Podcasts

#AI / data analytics / healthtech / informatics #Drug discovery

NovAliX partners with Chemical.AI to develop artificial intelligence toolkit for drug discovery

NovAliX, a drug discovery-focused contract research organisation (CRO), and Chemical.AI, an artificial intelligence (AI) company leveraging human expertise and cutting-edge AI technology for chemistry and pharmaceuticals, have created a strategic It is hoped that the affiliation will help create the most relevant AI solutions for drug developers. NovAliX brings 20… Read More

#Editor's Choice #News #Trending News

#CRISPR #Drug discovery #SLAS 2021

Horizon Discovery at SLAS2021 Digital

Horizon Discovery is sponsoring SLAS 2021. The company will be holding an innovative tutorial presentation on booth 114 which will cover the use of both pooled and arrayed screens in the drug discovery pipeline. Topics covered include: Arrayed screens in primary immune cells with co-culture endpoints Pooled CRISPR knockout screens with… Read More

#Editor's Choice #News

#AI #Assay development optimisation & technology #Biologics / Biotechnology #Cancer research #Drug development #Drug discovery #Vaccines

Latest issue of DDW now available

The Winter 2020/21 issue of DDW is now available in print and via the DDW App, featuring the latest innovation and insight from the drug discovery and development community. This season’s issue contains features on vaccines and immunology, AI and the US biotech sector plus expertise from companies such as… Read More

#Editor's Choice #News

#Antibodies #Covid-19 #Drug discovery

How to achieve accurate affinity profiling of a SARS-CoV-2 antibody in serum

Measuring antibody affinity under physiologically relevant conditions in complex mixtures like serum remains challenging but is critically important to furthering our understanding of the immune response and protection window in patients and vaccinated individuals. Fluidic Analytics’ application note explains why current technologies provide only an incomplete understanding of the… Read More

#Covid-19 #News

#AI / data analytics / healthtech / informatics #Assay development optimisation & technology #Drug development #Drug discovery #Narrated podcasts #Research

Innovation and Opportunity in Drug Discovery

Today’s episode on the topic of Innovation and Opportunity in Drug Discovery, covers 3 articles taken from the most recent Fall issue of DDW. These articles are titled: Japanese drug development: Where is the innovation, Where are the opportunities in global drug discovery, and New for Old: The value behind drug repurposing. These… Read More

#Podcasts

#Assay development & optimisation #Drug discovery #In vitro

Eurofins, a focus on drug discovery expertise

Eurofins Discovery is a CRO with a range of expertise in drug discovery. Christina Shasserre, Senior VP spoke to Lu Rahman about some of the company’s current COVID-related work as well as offering insight into the drug discovery landscape.   LR: Are you able to share some of Eurofins Discovery’s… Read More

#News #Opinion

#AI / data analytics / healthtech / informatics #Drug discovery

Precision medicine in the era of artificial intelligence

Dr Lotfi Chouchane and Dr. Javaid Sheikh, Weill Cornell Medicine-Qatar, outline the challenges and opportunities ahead for drug discovery Precision medicine is an emerging model for the next generation of clinical care that will capitalise on the dynamic interaction between individual biology, lifestyle, behaviour, and environment. It holds huge promise… Read More

#Exclusive Content #News #Trends & Analysis